In yesterday’s Wall Street session, Cns Pharmaceuticals Inc (NASDAQ:CNSP) shares traded at $0.11, up 5.41% from the previous session.
CNSP stock price is now -2.62% away from the 50-day moving average and -97.19% away from the 200-day moving average. The market capitalization of the company currently stands at $6.61M.
On August 24, 2020, Ladenburg Thalmann recently initiated its ‘Buy’ rating on the stock quoting a target price of $11
In other news, Gumulka Jerzy, Director bought 33,333 shares of the company’s stock on Feb 01 ’24. The stock was bought for $10,000 at an average price of $0.30. Upon completion of the transaction, the Director now directly owns 43,006 shares in the company, valued at $4730.66. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 01 ’24, Director Evans Carl Anthony bought 33,333 shares of the business’s stock. A total of $10,000 was incurred on buying the stock at an average price of $0.30. This leaves the insider owning 33,458 shares of the company worth $3680.38. A total of 1.04% of the company’s stock is owned by insiders.
During the past 12 months, Cns Pharmaceuticals Inc has had a low of $0.10 and a high of $70.00. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 1.81, and a quick ratio of 1.81. The fifty day moving average price for CNSP is $0.11824 and a two-hundred day moving average price translates $4.200445 for the stock.
The latest earnings results from Cns Pharmaceuticals Inc (NASDAQ: CNSP) was released for 2024-06-30. The company reported revenue of $5.63 million for the quarter, compared to $4.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 24.15 percent.
